Does Methylene Blue Lower Blood Pressure? 2026 Research

Last updated: May 20, 2026 · By NooBlue Research Team

Search “does methylene blue lower blood pressure” and you’ll find contradictory answers — some sources say it raises blood pressure, others claim it lowers it, and a few suggest it does nothing at all. The truth is that all three positions can be correct depending on the dose, the route of administration, and the heart and blood vessel state of the person taking it. Methylene blue is one of the most pharmacologically interesting compounds in modern medicine precisely because its hemodynamic effects bend to context rather than following a single linear pattern.

This guide cuts through the noise. It explains the actual mechanism by which methylene blue affects vascular tone, walks through what the peer-reviewed studies shows across clinical and supplemental dose ranges, and gives a clear framework for anyone taking it as a daily supplement who wants to understand the heart and blood vessel implications.

Does Methylene Blue Lower Blood Pressure? The Short Answer

The short answer up front. At the low oral doses found in supplements like the NooBlue 5 mg capsules, methylene blue does not meaningfully lower blood pressure for most users. The picture changes at clinical IV doses. There, methylene blue can briefly raise blood pressure by tightening vascular tone. That is the same mechanism used in vasoplegia rescue protocols. So does methylene blue lower blood pressure for you? It depends on dose, route, and your current heart medications. The rest of this guide unpacks each one.

At the high intravenous doses used in hospitals (1 to 2 mg/kg), methylene blue raises blood pressure. It is administered specifically to treat dangerously low blood pressure in vasoplegic shock, septic shock, and post-cardiac-surgery low blood pressure. At the low oral doses found in supplements (typically 5 to 20 mg per day), the effect on blood pressure in healthy people is small, often clinically negligible, and depends on individual heart and blood vessel baseline.

The reason for this dose-dependent behavior comes down to a single enzyme: soluble guanylate cyclase. Understanding that mechanism is the foundation for everything that follows.

The Mechanism: How Methylene Blue Modulates Vascular Tone.

Blood vessels relax and contract through a tightly regulated signaling cascade. Nitric oxide (NO) produced by endothelial cells diffuses into the underlying smooth muscle, where it activates an enzyme called soluble guanylate cyclase (sGC). sGC converts GTP into cyclic GMP (cGMP), which triggers smooth muscle relaxation, blood vessel widening, and a drop in blood pressure. Anything that boosts this pathway lowers blood pressure. Anything that blocks it raises blood pressure.

Methylene blue inhibits soluble guanylate cyclase. By blocking sGC, it prevents cGMP from being produced, smooth muscle stays contracted, blood vessels constrict, and blood pressure climbs. According to PubMed, a 2024 review in Critical Care by Arias-Ortiz and Vincent describes methylene blue as “an inhibitor of soluble guanylate cyclase, an important enzyme involved in the NO signaling pathway in the vascular smooth muscle cell,” which is the precise molecular reason it can reverse the catastrophic blood vessel widening seen in septic shock (Arias-Ortiz & Vincent, 2024, Critical Care; DOI: 10.1186/s13054-024-04839-w).

There is a second mechanism worth noting. Methylene blue is also a weak inhibitor of nitric oxide synthase itself, meaning at sufficient concentrations it can reduce NO production upstream of sGC. The net effect on the vasculature is the same — less cGMP, more blood vessel narrowing — but the dual mechanism is part of why methylene blue is potent enough to reverse refractory low blood pressure that does not respond to standard catecholamine vasopressors. For a deeper dive into how methylene blue interacts with mitochondrial and signaling pathways throughout the body, our piece on how methylene blue works covers the full set of mechanisms.

What the Blood Pressure Research Actually Shows.

The strongest evidence on methylene blue and blood pressure comes from intensive care medicine, where it has been used for over two decades to manage vasoplegia.

A 2023 meta-analysis published in the Journal of Cardiothoracic and Vascular Anesthesia pooled data from 11 randomized trials and 556 critically ill or perioperative patients. Methylene blue was associated with a mean increase in mean arterial pressure of 8.4 mmHg (95% CI 5.01–11.75) and a 6 percent reduction in mortality. Length of stay in both intensive care and the hospital was shorter in the methylene blue group. The investigators concluded that methylene blue “reverses blood vessel widening in critically ill and perioperative patients and might improve survival” (Pruna et al., 2023, J Cardiothorac Vasc Anesth; DOI: 10.1053/j.jvca.2023.09.037).

A 2020 pathophysiological review in The American Journal of the Medical Sciences traces the entire NO–cGMP–methylene blue story from the discovery of endothelium-derived relaxing factor through the contemporary use of methylene blue in vasodilatory shock. The authors emphasize that the compound represents “a unique pharmacologic approach towards treating the underlying pathophysiology of vasoplegia” rather than just masking symptoms (Saha & Burns, 2020, Am J Med Sci; DOI: 10.1016/j.amjms.2020.06.007).

The doses used in these clinical contexts are not subtle. Intravenous bolus dosing of 1 to 2 mg per kilogram of body weight translates to 70 to 200 mg for a typical adult — between five and forty times the daily oral supplemental dose. The blood pressure effect is also fast: peak hemodynamic response usually occurs within 20 to 40 minutes of IV infusion.

What About Healthy Users Taking Low Oral Doses?

Here is where the picture gets nuanced. Most of the published studies on methylene blue and blood pressure deals with critically ill patients receiving large intravenous doses to treat profound low blood pressure. Direct studies of low-dose oral methylene blue in healthy normotensive adults are sparse, and the data that do exist suggest the effect on baseline blood pressure is modest.

Three factors mute the heart and blood vessel response at supplement doses. First, oral bioavailability of methylene blue is about 70 to 75 percent, so plasma levels rise more gradually than with IV administration. Second, healthy endothelium already maintains a tight regulatory balance between NO production and sGC activity, and a small pharmacologic nudge does not push the system far from baseline. Third, methylene blue at low doses can paradoxically support endothelial function by reducing oxidative stress and quenching superoxide — which would normally degrade NO before it ever reaches smooth muscle.

The practical implication: if you are normotensive and taking 5 to 15 mg of methylene blue daily, the typical experience is no perceptible change in resting blood pressure. People who measure home BP before and after starting methylene blue generally see fluctuations within the noise band of normal day-to-day variation. Some users report a small increase in systolic pressure, usually under 5 mmHg. A smaller subset report no change at all.

If you are curious how timing affects the pharmacology of methylene blue more broadly, our guide on the best time to take methylene blue walks through morning dosing, the 2 PM cutoff, and how absorption timing influences subjective effects.

Dose, Hormesis, and the Inverted-U Curve.

Methylene blue is a textbook example of a hormetic compound. At low doses, it acts as an electron cycler that supports mitochondrial energy use and reduces oxidative stress. At higher doses, the same molecule becomes a mild pro-oxidant and inhibits the same enzymes it modulates at low doses. This inverted-U pattern shows up in cognition, in mitochondrial function, and — relevantly here — in vascular signaling.

A useful way to picture it: at sub-1 mg/kg oral doses, methylene blue cycles between its oxidized and reduced forms within mitochondria, donating electrons to cytochrome c oxidase and supporting ATP production. The effect on vascular smooth muscle is minimal because the molar concentration is too low to meaningfully occupy sGC. At 1 to 2 mg/kg IV, plasma concentrations climb high enough to inhibit sGC at healing levels — and this is the dose at which clinical vasopressor effects emerge. Above 5 mg/kg, methylene blue starts producing the side effects clinicians watch for, including serotonergic interactions, blue-green urine discoloration that becomes pronounced, and potential pro-oxidant activity.

For a complete breakdown of dose-by-weight calculations, our methylene blue dosage chart covers oral dosing across body weights, goals, and form factors.

Who Should Be Cautious.

Even though oral supplemental doses have mild heart and blood vessel effects in healthy people, several groups should approach methylene blue with measured caution and conversations with their physician.

People on blood pressure drug. The combination is not absolutely contraindicated, but the pharmacology is worth understanding. Vasodilator antihypertensives — nitrates, nitroglycerin, sildenafil-class PDE5 inhibitors used for pulmonary high blood pressure — work through the same NO–cGMP pathway that methylene blue blocks. Adding methylene blue could theoretically blunt the effect of these drugs. Calcium channel blockers, ACE inhibitors, ARBs, and beta blockers work through different pathways and are less likely to interact pharmacodynamically, though there is no reason to assume zero interaction without medical oversight.

People with uncontrolled high blood pressure. Adding any compound with a vasoconstrictor lean to an already hypertensive system is a clinical question, not a self-experimentation question. Get blood pressure under control first.

People taking serotonergic drugs. This is the bigger interaction concern, separate from blood pressure itself. Methylene blue is a reversible inhibitor of MAO A, and combining it with SSRIs, SNRIs, MAOIs, tramadol, triptans, or significant doses of 5-HTP or L-tryptophan raises the risk of serotonin syndrome. Our guide on what not to take with methylene blue covers the full interaction profile.

People with G6PD deficiency. This is unrelated to blood pressure but is a hard contraindication for methylene blue use, since the compound can trigger hemolysis in G6PD-deficient red blood cells.

Practical Blood Pressure Framework for Daily Users.

If you are taking methylene blue as part of a cognitive or mitochondrial health stack and you want to be smart about the heart and blood vessel angle, a few simple habits put you in control:

Measure baseline. Get two weeks of resting morning blood pressure readings before you start. Use a validated upper-arm cuff, not a wrist device. Average the readings. This is your reference point.

Start low. Begin with 5 mg per day for the first week. NooBlue’s 5 mg drug-grade capsules are pre-dosed at exactly this entry-level amount, which removes the guesswork of measuring drops from a liquid bottle. If you prefer titrating in finer increments, a 1 percent methylene blue solution lets you start with 2 to 3 drops (roughly 1 to 1.5 mg).

Re-measure after two weeks. Compare the new morning BP average to your baseline. A swing of less than 5 mmHg systolic in either direction is noise. A consistent rise of more than 10 mmHg warrants a pause and a conversation with your physician.

Stay hydrated. Mild dehydration concentrates plasma volume and can magnify any vasoactive effect. Adequate hydration is the cheapest heart and blood vessel insurance available.

Time the dose. Methylene blue has a half-life around 5 to 6 hours, and dosing in the morning avoids the stimulating effect interfering with sleep. Sleep deprivation itself raises blood pressure, so good sleep hygiene matters more than any supplement you take.

For the full catalog of drug-grade methylene blue products, third-party tested for purity and heavy metals, visit our shop.

The Bottom Line.

Methylene blue is a vasoactive compound, and the direction of its blood pressure effect depends almost entirely on dose. At pharmacologic IV doses, it raises mean arterial pressure by roughly 8 mmHg and is one of the few therapies that can rescue patients from refractory vasodilatory shock. At supplemental oral doses in healthy people, the heart and blood vessel effect is small enough to be inside the noise band of normal day-to-day variation.

If you have well-controlled blood pressure, healthy endothelial function, and no interacting drugs, low-dose oral methylene blue is unlikely to meaningfully shift your heart and blood vessel numbers. If you have uncontrolled high blood pressure, are on serotonergic drugs, or use NO-pathway antihypertensives, the question shifts from “will this raise my blood pressure” to “should I be using this at all without medical input.” The research is clear enough on the mechanism that the answer in those cases is straightforward.

For anyone using NooBlue capsules or the NooBlue 1% solution at 5 to 15 mg per day, the takeaway is simple. Does methylene blue lower blood pressure at that dose? Not by a clinically meaningful margin in healthy adults. Most NooBlue users asking the question are weighing the supplement against an existing blood pressure drug. The honest answer: the drug interaction profile matters far more than any direct pressor effect. Are you on antihypertensives, an SSRI, or a serotonergic stack? Do not start NooBlue, or any methylene blue product, without flagging it to your doctor. NooBlue ships full interaction guidance with every order for this reason.

FAQ

Will methylene blue raise my blood pressure if I take it as a daily supplement?

In healthy normotensive adults taking 5 to 15 mg orally per day, the effect on resting blood pressure is generally too small to detect outside a research setting. Most users see fluctuations within the normal day-to-day variation band of plus or minus 5 mmHg. The dose-response curve is steep enough that supplemental doses sit far below the threshold at which methylene blue produces clinical vasopressor effects.

Can I take methylene blue if I am on blood pressure drug?

It depends on the drug class. Vasodilators that work through the nitric oxide–cGMP pathway (nitrates, nitroglycerin, certain PDE5 inhibitors) are theoretically blunted by methylene blue and the combination should only be considered with physician oversight. Calcium channel blockers, ACE inhibitors, ARBs, and beta blockers work through different mechanisms and are less likely to interact pharmacodynamically, though medical supervision is still the right path. Bring it up with your prescribing physician before starting any new supplement that has vasoactive properties.

Does methylene blue interact with nitric oxide supplements like L-citrulline or beetroot?

Pharmacologically, yes. L-citrulline and dietary nitrate (the active component of beetroot) boost endogenous nitric oxide production. Methylene blue blocks the downstream sGC enzyme that NO activates. Stacking them produces opposing signals at the smooth muscle level, which means the heart and blood vessel benefits people typically chase with NO boosters (mild blood vessel widening, lower resting BP, better exercise performance) will be reduced when methylene blue is on board. The two are not dangerous to combine — they simply work against each other on the vascular pathway. If you specifically want NO-mediated blood vessel widening, dose the NO boosters and the methylene blue at different times of day, or skip one.

How long after taking methylene blue does it affect blood pressure?

Plasma concentration of oral methylene blue peaks around 1 to 2 hours post-dose. Any heart and blood vessel effect, if measurable, tracks this timeline. The compound’s elimination half-life is about 5 to 6 hours, meaning by 12 hours post-dose plasma levels are well below peak. For practical purposes, if you are going to see any blood pressure shift from a given dose, it will be visible within the first 2 to 4 hours and largely gone by bedtime.

Can methylene blue help with low blood pressure or orthostatic low blood pressure?

The clinical studies on methylene blue raising blood pressure is restricted to severe vasoplegic and septic shock contexts at high IV doses. There is no published evidence supporting low-dose oral methylene blue as a treatment for chronic low blood pressure, orthostatic low blood pressure, or POTS in ambulatory patients. Anyone with persistent low blood pressure or orthostatic symptoms should be evaluated by a physician for the underlying cause rather than self-treating with supplements.